Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 45 citations in OpenAlex.

1. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015
   Trial
2. Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).Cancer · 2013
   Trial
3. A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma.Vaccines · 2020
   Article
4. Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.PloS one · 2019
   Article
5. Sunitinib in the treatment of metastatic renal cell carcinoma.Therapeutic advances in urology · 2016
   Review
6. Sequencing systemic therapies for metastatic kidney cancer.Current treatment options in oncology · 2015
   Review
7. Dual VEGF/VEGFR inhibition in advanced solid malignancies: clinical effects and pharmacodynamic biomarkers.Cancer biology & therapy · 2014
   Article
8. A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies.Cancer chemotherapy and pharmacology · 2014
   Article
9. Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea.The Korean journal of internal medicine · 2014
   Article
10. Safety and feasibility of targeted agent combinations in solid tumours.Nature reviews. Clinical oncology · 2013
    Review
11. A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.Clinical genitourinary cancer · 2013
    Article
12. The VHL/HIF axis in clear cell renal carcinoma.Seminars in cancer biology · 2013
    Review
13. Vegfa protects the glomerular microvasculature in diabetes.Diabetes · 2012
    Article
14. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.Cancer · 2012
    Article
15. Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.Molecular cancer therapeutics · 2012
    Review
16. New insights into the biology of renal cell carcinoma.Hematology/oncology clinics of North America · 2011
    Review
17. Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.British journal of cancer · 2011
    Article
18. Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA.NDT plus · 2011
    Article
19. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.British journal of cancer · 2011
    Review
20. Combination therapy for renal cell cancer: what are possible options?Oncology · 2011
    Review

Corrections and comments

• Comment on
  Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.2009

Authors and funding

11 authors at 3 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as